Literature DB >> 23194471

Medical practice and legal background of decisions for severely ill newborn infants: viewpoints from seven European countries.

P J J Sauer1, J H H M Dorscheidt, A A E Verhagen, J H Hubben.   

Abstract

AIM: To comparing attitudes towards end-of-life (EOL) decisions in newborn infants between seven European countries.
METHODS: One paediatrician and one lawyer from seven European countries were invited to attend a conference to discuss the practice of EOL decisions in newborn infants and the legal aspects involved.
RESULTS: All paediatricians/neonatologists indicated that the best interest of the child should be the leading principle in all decisions. However, especially when discussing cases, important differences in attitude became apparent, although there are no significant differences between the involved countries with regard to national legal frameworks.
CONCLUSION: Important differences in attitude towards neonatal EOL decisions between European countries exist, but they cannot be explained solely by medical or legal reasons. ©2012 The Author(s)/Acta Paediatrica ©2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 23194471     DOI: 10.1111/apa.12073

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  3 in total

1.  Involuntary euthanasia of severely ill newborns: is the Groningen Protocol really dangerous?

Authors:  P Voultsos; F Chatzinikolaou
Journal:  Hippokratia       Date:  2014 Jul-Sep       Impact factor: 0.471

Review 2.  Periviable birth: A review of ethical considerations.

Authors:  E Gkiougki; I Chatziioannidis; A Pouliakis; N Iacovidou
Journal:  Hippokratia       Date:  2021 Jan-Mar       Impact factor: 0.471

3.  Bioethical Decisions in Neonatal Intensive Care: Neonatologists' Self-Reported Practices in Greek NICUs.

Authors:  Maria Dagla; Vasiliki Petousi; Antonios Poulios
Journal:  Int J Environ Res Public Health       Date:  2020-05-15       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.